Rainer Haag is a Professor at the Department of Chemistry, Freie Universität Berlin, leading the Haag Group in the Institute of Chemistry and Biochemistry. His research focuses on biodegradable and sustainable materials, dynamic hydrogels, and polymeric nanosystems for biomedical applications. Department of Chemistry, Freie Universität Berlin Member of SFB 1449: Dynamic Hydrogels at Biointerfaces Collaborator in the StemGel startup project Co-founder of CSR|Berlin interdisciplinary research institute Research Interests: Development of stimuli-responsive polymers, multivalent virus inhibitors, and functional biointerfaces. Key projects include: Antiviral coatings using heteromultivalent polymers Thermoresponsive hydrogels for stem cell expansion Graphene derivatives for bacterial capture and disinfection Lignin upcycling for sustainable resin materials Supramolecular nanosystems for drug delivery Publication Trends highlight interdisciplinary work in polymer chemistry, nanotechnology, and biomedical applications. Recent articles focus on: 2D polyglycerols for virus interactions Redox-responsive nanogels Mucus-inspired adhesive hydrogels Tumor-targeting micelles Bacterial disinfection using graphene composites Labs & Collaborations include the Polymeric and Supramolecular Nanosystems subgroup, the Dynamic Hydrogels and Biointerfaces team, and partnerships with MIT in developing bioinspired adhesives. His group contributes to DFG-funded SFB 1449 and CSR|Berlin initiatives.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Prof. Dr. Deniz Tasdemir is a Full Professor (W3) of Marine Natural Products Chemistry at GEOMAR Helmholtz-Zentrum für Ozeanforschung Kiel and serves as Director of the GEOMAR-Biotech center and Head of the Marine Natural Product Chemistry Research Unit. Her career spans institutions including the National University of Ireland Galway and UCL School of Pharmacy. PhD in Pharmacy, ETH Zurich (1997) Post-doctoral work, University of Utah (2001) Dr. Helmut Legerlotz Fellowship, University of Zurich (2002-2025) Her research focuses on marine chemical ecology , metabolomics , and bioprospecting for bioactive compounds from sponges, algae, and marine microbiomes. Recent work explores seagrass pathogen reduction, microbiome interactions, and aquafeed applications. Scientific awards include: Waters Award for Natural Products Innovation (2016) Egon Stahl Silver Medal (2005) Pierre Fabre Prize (2004) ETH Zurich Medal (1997) She leads collaborative projects on ocean sustainability and marine drug discovery, with editorial roles in Marine Drugs , Planta Medica , and Phytochemistry Letters .
Prof. Dr. Oliver Krüger is a behavioral ecologist and evolutionary biologist at Bielefeld University 's Faculty of Biology , where he leads the Department of Animal Behaviour since 2013. His research spans avian and marine mammal systems, focusing on life history strategies, parasite-host interactions, and environmental adaptation. Education: Biology studies at Bielefeld University (1994-1996) MSc in Oxford (1996-1997) PhD at Bielefeld University with Fritz Trillmich and Jan Lindström (1998-2000) Research Themes: Behavioral ecology, evolutionary biology, and population dynamics across tropical and temperate ecosystems. Key projects include NC³ (Niche Choice/Construction) and studies on Galápagos sea lions, common buzzards, and pinniped species. Scientific Leadership: Spokesperson, SFB TRR 212 "NC³" (2018-2025) Advisory Board member: German Ornithologists Union, IUCN SSC pinniped group, German Primate Centre Peer review roles: Humboldt Foundation, DFG, HFSP, NSF Awards: Leopoldina Prize (2001) Niko Tinbergen Award (2008) DFG Heisenberg Professorship (2010-2015)
Prof. Friederike Ebner holds the Chair of Infection Pathogenesis at the Technical University of Munich (TUM) since 2023, within the TUM School of Life Sciences. Her research focuses on the immunobiology of parasite infections, particularly studying gastrointestinal helminths like Ascaris suum and their interactions with host immune systems to design novel intervention strategies. She also develops biomedical models for studying infectious diseases. Educational Background: Friederike Ebner earned a biotechnology degree from TU Berlin and Dongseo University (South Korea). She completed her PhD in biology at Humboldt University Berlin (2014), followed by postdoctoral research in immunology at Freie Universität Berlin, where she became an assistant professor before moving to TUM. Research Interests: Her work spans helminth-host immune dynamics, vaccine development, microbiome interactions in parasitic infections, and translational models for human diseases. Key topics include Th2/Th1 immune balance, helminth-derived immunomodulators, and xenotransplantation safety. Notable Contributions: Her recent studies address diagnostic methods for ascariasis, microbiome roles in helminth survival, and immunotherapeutic applications of parasite products. Current efforts emphasize bridging fundamental immunology with clinical and veterinary applications. Professional Activities: Prof. Ebner teaches immunology and parasite biology at TUM while maintaining active collaborations in global health and infectious disease research. She advocates for interdisciplinary approaches to address knowledge gaps in parasitology and vaccinology.
Prof. Ralph Hückelhoven is a Professor of Phytopathology at the Technical University of Munich (TUM), affiliated with the TUM School of Life Sciences. His research focuses on the molecular and biological mechanisms underlying plant diseases, particularly plant immunity, pathogen exploitation of signal transduction, and host-pathogen interactions. He leads the Chair of Phytopathology at TUM since 2006, following academic roles at universities of Kiel and Hohenheim. Education: PhD (1999) and habilitation in molecular phytopathology (2005) from Justus Liebig University Giessen, after a biology degree at RWTH Aachen University. Awards: Julius Kühn Prize (2004) and leadership of a DFG Junior Research Group (2002-2006). His research spans plant immunity at cellular and molecular levels, including studies on receptor kinases (e.g., MIK2, LORE), RAC GTPases (e.g., RACB), and metabolomics-driven insights into pathogen resistance. He has published over 100 peer-reviewed articles, examining topics like fungal toxins, volatile signaling, and crop disease management. Key publications include work on Arabidopsis immune receptors, barley powdery mildew susceptibility factors, and Fusarium head blight resistance. Research integrates genetics, proteomics, and metabolomics to advance disease-resistant crop development. His lab investigates host-pathogen interactions across scales—from molecular signaling to field epidemiology—contributing to sustainable agricultural strategies against plant pathogens.
Dr. Angelika Rambold is a Group Leader at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany, heading the Laboratory for Metabolic Organelle Networks in Immunology within the Department of Developmental Immunology. Previously affiliated with the University of Münster's Center for Molecular Biology of Inflammation (ZMBE) and Institute of Medical Biochemistry until January 2025, she investigates how intracellular organelle networks regulate immune cell function during inflammation, infection, and metabolic stress. Her research centers on dynamic interactions between mitochondria, lysosomes, lipid droplets, and autophagosomes during cellular adaptation to nutrient deprivation and pathogen challenge. Key interests include organelle communication mechanisms in immune cell activation, metabolic reprogramming in T cells and macrophages, and how defects in organelle networks drive primary immunodeficiencies like Chediak-Higashi syndrome. She employs advanced live-cell microscopy, super-resolution imaging, metabolomics, and single-cell transcriptomics to dissect these processes in primary immune cells and human disease models. Analysis of her publication record reveals consistent focus on mitochondrial dynamics as a central regulator of immune cell metabolism and fate determination. Landmark studies demonstrate TFEB-mediated itaconate synthesis for bacterial control in macrophages and coordinated organelle network responses during starvation, establishing critical links between organelle communication, immunometabolism, and disease pathogenesis across multiple immune cell types. Dr. Rambold serves as a supervisor in the Cells in Motion International Max Planck Research School (CiM-IMPRS) Graduate Programme, mentoring PhD students in interdisciplinary research. Her laboratory maintains active collaboration with the Center for Chronic Immunodeficiency (CCI) at the University of Freiburg to translate basic findings on organelle-mediated immune defects into clinical insights for patient-oriented research.
Prof. Oliver Seitz leads the Bioorganic Synthesis research group at the Department of Chemistry, Faculty of Mathematics and Natural Sciences, Humboldt University of Berlin. His lab focuses on cutting-edge chemical biology approaches for protein/nucleic acid interrogation, with recent work advancing DNA/RNA-programmed assemblies for cellular imaging and therapeutic applications. Research spans chemical protein synthesis, glycoprotein/phosphoprotein engineering, and nucleic acid-templated reactions. Key innovations include Forced Intercalation (FIT) probes for wash-free RNA imaging, loss-of-affinity principles for catalytic efficiency, and peptide-PNA conjugates for targeted cellular delivery. The group actively develops tools for live-cell protein labeling and biomolecular spatial screening. Recent publications (2021-2024) emphasize fluorescence-based detection systems, catalytic templated reactions, and therapeutic peptide synthesis. Trends show increasing sophistication in multi-dye probes, glycan engineering, and RNA-triggered pro-drug activation. Scientific awards include: Max Bergmann Award (2019) Prof. Seitz actively advises doctoral students, with recent graduates Marvin Björn Stutz (2023, magna cum laude ), Dino Gluhacevic von Krüchten (2023, summa cum laude ), and Sophie Schöllkopf (2023, magna cum laude ). Current PhD candidates include Ekaterina Kazakova (glycoprotein synthesis), Alina Herfort (phosphoproteins), and Lina-Marie Beck (peptide-nucleic acid conjugates), with postdocs like Dr. Mandana Oloub (viscosity sensors). The Bioorganic Synthesis lab operates within Berlin's vibrant chemical research ecosystem, utilizing specialized techniques for chemical protein synthesis and nucleic acid detection. Recent team growth reflects ongoing projects in RNA imaging, catalytic templated reactions, and therapeutic conjugate development, supported by open positions for new researchers.
Prof. Dr. Kathrin Schumann is an Assistant Professor at the Technical University of Munich (TUM), leading the 'Engineering Immune Cells for Therapy' group within the TUM School of Medicine and Health. Her research focuses on CRISPR-based engineering of human immune cells to develop novel therapies for autoimmune and tumor diseases. She holds a doctorate from the Max Planck Institute of Biochemistry and has conducted postdoctoral research at the University of California, San Francisco, under Professors Alex Marson and Jeffrey Bluestone. Dr. Schumann’s academic career includes a Presidential Postdoc Fellowship at Novartis (Basel) and a tenure-track appointment at TUM since 2018. Her work emphasizes genomic editing of T cells to study gene function and improve cell therapy safety. Key research themes include CRISPR-mediated gene silencing, T cell receptor engineering, and HIV-host interaction studies. Education: Bachelor/Master in Biochemistry, University of Tübingen PhD, Max Planck Institute of Biochemistry (Martinsried) Postdoc, University of California, San Francisco (UCSF) Her research has yielded breakthroughs in CRISPR applications for T cell therapy, including PD-1 disruption to enhance anti-tumor efficacy and targeted editing of T cell receptors. Awards include a DFG research grant (2016). Notable achievements include the development of CRISPR ribonucleoprotein platforms for primary T cells and insights into metabolic checkpoints in T cell exhaustion. Her lab collaborates globally to translate CRISPR-based discoveries into clinical therapies.
Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.
Michael T. Monaghan is a Professor at the Faculty of Biology, Chemistry and Pharmacy, Freie Universität Berlin, and leads the Research Group in Molecular Ecology and Genomics at the Leibniz Institute of Freshwater Ecology and Inland Fisheries (IGB). His work bridges evolutionary biology, molecular ecology, and environmental monitoring, focusing on freshwater systems and urban aquatic habitats. Education: B.S. (The Ohio State University, 1995), M.S. (Idaho State University, 1998), Dr. sc. nat. (ETH Zürich, 2002) Key Positions: Senior Scientist/Research Group Leader at IGB (2008–present), Visiting Professor at Duke-NUS Medical School (2016), Guest Professor at Ehime University (2015–2016) Dr. Monaghan's research explores freshwater biodiversity dynamics using molecular tools like metabarcoding and phylogenomics. His team investigates how environmental changes—climate warming, urbanization, pollution—affect microbial and insect communities, with a focus on eDNA applications and ecohydrology. His publications (2022–2025) span topics such as climate-driven plankton shifts, urban habitat adaptation by bees, toxin genetics in algae, and metagenomic monitoring of aquatic systems. Collaborative projects like BiNatUr and ODER~SO emphasize urban resilience and disaster ecology. Teaching includes data science in biology, evolutionary ecology, and environmental genomics at Freie Universität Berlin and the Institute of Computer Science. He mentors doctoral and master’s students in molecular ecology and trains interns in biodiversity genomics. Lab Members: Dr. Dagmar Frisch (Scientific Staff) Dr. Katrin Kiemel (Postdoc) Elisabeth Funke (Research Technician) Doctoral Candidates: Onur Erk Kavlak, Athena Karapli-Petritsopoulou, Daniel Wewer
Professor Stephan A. Sieber is a leading researcher in bioorganic chemistry at the Technical University of Munich (TUM), where he holds the Chair of Organic Chemistry II within the TUM School of Natural Sciences. His research program focuses on developing new drugs against multidrug-resistant bacteria through a multi-disciplinary approach that integrates synthetic chemistry, functional proteomics, microbiology, and protein biochemistry. His laboratory has made significant contributions to identifying unprecedented antibacterial targets beyond the scope of current antibiotics and exploiting these for chemical manipulation. Recent work has increasingly incorporated machine learning approaches to accelerate antibiotic discovery, with notable publications on AI-guided pipelines, drug-target interaction prediction, and high-throughput screening optimization. Sieber's research has resulted in the discovery of new active substances, some of which are currently being optimized for medical applications. His group's publications reveal a strong focus on chemical proteome mining, natural product mode of action studies, and novel antibacterial target identification. The lab has published extensively in top journals including Nature Chemistry, Nature Communications, and ACS Central Science. Inhoffen Medal (2024) Max Bergmann Medal (2023) ERC Advanced Grant (2023) Merck Future Insight Prize (2020) Klaus Grohe Prize (2020) ERC Consolidator Grant (2016) Professor Sieber leads an active research group that maintains a strong presence in the scientific community through regular publications, conference presentations, and collaborations. His laboratory website and BlueSky presence (@sieberlab.bsky.social) demonstrate ongoing research activities and engagement with the broader scientific community. He has successfully secured significant research funding including multiple ERC grants that have supported his innovative work in antibiotic discovery.
Professor Charlotte Kloft is Head of the Department of Clinical Pharmacy & Biochemistry at the Institute of Pharmacy, Free University of Berlin since 2011, and spokesperson for the interdisciplinary Graduate Research Training Program PharMetrX 'Pharmacometrics and Computational Disease Modelling' since 2008. She previously served as Professor and Head of the Department of Clinical Pharmacy at Martin-Luther-University Halle-Wittenberg (2005-2011) and as Scientific Assistant/Senior Assistant at Freie Universität Berlin (1999-2005). Her academic credentials include a habilitation in Clinical Pharmacy from Freie Universität Berlin (2003) and a Dr. rer. nat. (summa cum laude) from the same institution (1997). She earned her license as a pharmacist in 1992 after completing pharmacy studies at Johannes Gutenberg-University, Mainz (1987-1991). Professor Kloft's research focuses on pharmacometrics, computational disease modeling, and therapeutic drug monitoring across multiple therapeutic areas. Her work bridges pharmaceutical sciences with clinical practice, with particular emphasis on personalized dosing strategies for oncology, antimicrobial resistance, and inflammatory bowel diseases. She has pioneered research in optimizing drug dosing through pharmacokinetic/pharmacodynamic modeling, with applications in both antibiotic and cancer therapies. Her recent publications demonstrate a strong evolution toward integrating advanced computational approaches with clinical pharmacology, including machine learning applications in pharmacometrics, personalized dosing strategies for biologics during pregnancy, and developing nationwide infrastructure for therapeutic drug monitoring in cancer therapy through the ON-TARGET study. Academic Center of Excellence of Pharsight (now Certara), USA (since 2000) Habilitationsreisestipendium of Dr. August and Dr. Anni Lesmüller-Stiftung (2002) Ernst-Reuter-Preis of Ernst-Reuter-Gesellschaft (1998) Joachim-Tiburtius-Preis of Berlin Senate (1998) Young Investigator Award of EORTC-PAMM (1997) Professor Kloft has successfully supervised numerous doctoral students whose research spans diverse areas including CAR-T cell therapy, antimicrobial resistance, inflammatory bowel disease treatment optimization, and pharmacokinetic modeling of novel therapeutic agents. Her research group has secured significant funding for projects including GlobalResist, ON-TARGET, ABIMMUNE, COMBINATORIALS, and TAIN. She leads a vibrant research ecosystem at the Free University of Berlin with strong collaborations across Europe and internationally, maintaining state-of-the-art laboratory facilities including Biosafety Level 2 certified labs for infectious disease research.
Prof. Dr. Jörg Stülke is a full Professor of Microbiology and Head of the Department of General Microbiology at the Institute of Microbiology and Genetics, University of Göttingen. He has held this position since 2003 and leads an active research group focused on bacterial metabolism and gene regulation. His research spans two major model systems: the pathogenic bacterium Mycoplasma pneumoniae and the well-studied Bacillus subtilis . His group employs systems-level approaches including transcriptomics, metabolomics, and bioinformatics to understand metabolic regulation and gene expression. Key interests include protein phosphorylation, RNA-mediated regulation, mRNA processing, and the role of second messengers such as cyclic di-AMP in bacterial physiology and pathogenicity. The recent publications reveal a strong trend in molecular microbiology, functional genomics, and systems biology. His work often integrates experimental and computational methods, particularly evident in the development and maintenance of the SubtiWiki database for B. subtilis . The research bridges fundamental mechanisms of life with applications in understanding bacterial virulence and cellular homeostasis. He is affiliated with several graduate programs under the Göttingen Graduate Center for Neurosciences, Biophysics, and Molecular Biosciences (GGNB), including: Molecular Biology (IMPRS) Biomolecules: Structure - Function - Dynamics (GZMB) Molecular Biology of Cells (GZMB) Microbiology and Biochemistry Genome Science (IMPRS) While no individual students are listed, he clearly supervises doctoral candidates through these programs. His group has secured significant research output, including publications in Science , Nucleic Acids Research , and PLOS Pathogens , indicating successful grant funding and collaborative research. The lab maintains a dedicated website at http://genmibio.uni-goettingen.de/ , which serves as a hub for research activities and resources like SubtiWiki.
